Uterine cavity anti-adhesion isolation support and distraction device thereof
By using a uterine cavity anti-adhesion isolation stent with degradable zinc alloy material and polymer diaphragm, combined with a stent opening device, the problem of the high recurrence rate of isolation stents in the prior art is solved, and the endometrium is realized Effective isolation and self-degradation reduce the risk of infection and improve postoperative recovery effect.
Patent Information
- Application Number
- CN202410999743.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, when treating uterine adhesions, the isolation stent requires secondary surgery, which is prone to infection and requires oral estrogen, which increases the risk of venous thrombosis and has a high recurrence rate, making it difficult to effectively prevent postoperative uterine adhesions.
A uterine cavity anti-adhesion isolation stent made of degradable zinc alloy material is designed. Combined with a degradable polymer diaphragm, the degradation speed is adjusted through the notch structure to achieve self-degradation in the uterine cavity without secondary surgery, and equipped with The stretching device performs a one-time stretching and release.
Physical spatial isolation of the endometrium of the uterine cavity is achieved, postoperative adhesions are avoided, infection risk is reduced, estrogen use is reduced, patients' postoperative recovery effect is improved, and chronic inflammation is reduced through antibacterial effects.
Smart Images

Figure CN118924526A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical devices, and in particular to an anti-adhesion isolation bracket for uterine cavity and a propping device thereof. Background Art
[0002] Intrauterine adhesion refers to the adhesion between the cervix and the uterine wall caused by the destruction of the endometrial basal tissue structure and the loss of endometrial regeneration function due to radiotherapy, intrauterine surgery, low estrogen status, and infection. Severe intrauterine adhesions will lead to amenorrhea, infertility, spontaneous abortion, etc. in women of childbearing age.
[0003] At present, the common method for treating intrauterine adhesions is to first perform hysteroscopic intrauterine adhesion lysis (TCRA) and then place a physical barrier in the uterine cavity (while taking oral estrogen). However, within one month after the adhesion lysis surgery, in the early stage of endometrial scar repair, patients generally have problems such as granulation hyperplasia, inflammatory exudation and membranous adhesions. According to statistics, about 62.5% of patients will have intrauterine adhesions again after surgery. Therefore, preventing this postoperative intrauterine adhesion has gradually become the focus of clinical research.
[0004] The isolation stent used in the prior art requires a second surgery to remove it after implantation and postoperative recovery, because the tail thread left during the operation is prone to re-infection; other methods include using gel products to prevent intrauterine adhesions, but they need to be used with balloons, which can also cause infection during use. Whether it is an isolation stent or a gel product, a certain dose of estrogen needs to be taken orally after use, and the intake of estrogen increases the risk of venous thrombosis in patients.
[0005] Therefore, how to optimize the design of isolation stents to prevent intrauterine adhesions is a problem that needs to be solved. Summary of the invention
[0006] In order to solve at least one aspect of the above problems and defects in the prior art, the embodiments of the present invention provide an intrauterine anti-adhesion isolation stent and its expansion device, which prevents postoperative intrauterine adhesion through physical space isolation, and can be self-degraded in the uterine cavity without the need for secondary surgery to remove, thus avoiding infection. The technical solution is as follows:
[0007] According to one aspect of the present invention, a uterine cavity anti-adhesion isolation stent is provided.
[0008] The uterine cavity anti-adhesion isolation stent comprises:
[0009] The support frame comprises at least two support tubes, wherein at least two support tubes are made of a degradable zinc alloy material;
[0010] A notch is provided on the surface of each of the at least two support tubes, and at least one notch is provided on the surface of each support tube;
[0011] A degradable membrane is disposed between at least two support tubes and fixedly connected to the at least two support tubes through a notch, and the degradable membrane is configured to be foldable or unfoldable;
[0012] The degradation rate of the intrauterine anti-adhesion isolation stent is adjusted by coupling characteristic parameters of the support frame, the notch or the degradable diaphragm.
[0013] In some embodiments, the degradable zinc alloy material contains other alloy chemical elements besides zinc, including at least one of Cu, Li, Mn, Mg, Ca, Sr, Fe, Ag, Co, Cr, Ti, Sn, Si, Se, Ge, or any combination thereof.
[0014] In some embodiments, the number of at least two support tubes is two, each support tube is a hollow tube segment, each support tube has an outer diameter ranging from 1.3 to 2.3 mm, a wall thickness less than or equal to 0.1 mm, a length ranging from 33 to 42 mm, and a surface roughness less than or equal to 0.8 μm.
[0015] The at least two support tubes are formed by using a tube material through a drawing process.
[0016] Specifically, when the pipe is drawn, the deformation amount of a single pass ranges from 5% to 25%, and the drawing rate ranges from 0.15 to 5 mm / s.
[0017] Furthermore, the pipe is subjected to annealing treatment each time it is continuously broken for a predetermined number of times, the annealing temperature is 125-325° C., and the annealing time is 15-60 minutes.
[0018] The room temperature yield strength of the degradable zinc alloy material is greater than or equal to 150 MPa, the tensile strength is greater than or equal to 200 MPa, and the elongation is greater than or equal to 10%.
[0019] In some embodiments, the degradable membrane is made of a degradable polymer material with a characteristic viscosity greater than or equal to 0.8 dl / g. The degradable polymer material is one of polylactic acid-glycolic acid copolymer, poly (L-lactide), polydioxanone, polycaprolactone, or any combination thereof.
[0020] Specifically, the shape of the degradable membrane is a sector or a trapezoid, wherein the length of the long side of the sector or trapezoid is in the range of 26 to 35 mm, the length of the short side is in the range of 10 to 12 mm, the height is in the range of 27 to 40 mm, and the thickness of the degradable membrane is in the range of 0.2 to 0.4 mm.
[0021] In some embodiments, the characteristic parameters for adjusting the degradation rate of the intrauterine anti-adhesion isolation stent include: one of the length, outer diameter, wall thickness, cross-sectional area, cross-sectional diameter, and cross-sectional side length of the stent, or any combination thereof.
[0022] Specifically, the length of the support frame is in the range of 33 to 42 mm; the outer diameter of the support frame is in the range of 1.3 to 2.3 mm; and the wall thickness of the support frame is less than or equal to 0.1 mm.
[0023] In some embodiments, the above characteristic parameters also include: the number of slots on each support tube, the shape of the slots, the area of the slots, the side length of the slots, or any combination thereof.
[0024] Specifically, the notch penetrates the support tube or the wall of the support tube; the number of notches opened on each support tube is 20 to 30; the area of the notch ranges from 0.9 to 3.5 mm 2 ; The length of the slot side includes the long side and the short side, wherein the long side ranges from 3 to 7 mm and the short side ranges from 0.3 to 0.5 mm.
[0025] In some embodiments, the above characteristic parameters also include: the thickness of the degradable membrane, and the thickness ranges from 0.2 to 0.4 mm.
[0026] In some embodiments, after the intrauterine anti-adhesion isolation stent is implanted into the uterine cavity, the variation pattern of its degradation rate includes:
[0027] Increases as the length and / or cross-section of the support decreases;
[0028] It increases with the number of notches;
[0029] It increases as the thickness of the degradable membrane decreases.
[0030] In some embodiments, when the outer diameters of the two support tubes are 1.3-1.8 mm, the area of the notches is 0.9-3.5 mm 2 When the thickness of the degradable diaphragm is 0.2 to 0.3 mm, the degradation time of the intrauterine anti-adhesion isolation stent after implantation into the uterine cavity is 1 to 3 months.
[0031] In some embodiments, when the outer diameters of the two support tubes are 1.3 to 2.3 mm, the area of the notches is 2.2 to 3.5 mm. 2 When the thickness of the degradable diaphragm is 5 to 10 μm, the degradation time of the intrauterine anti-adhesion isolation stent after implantation in the uterine cavity is 3 to 6 months.
[0032] According to another aspect of the present invention, a device for expanding an intrauterine anti-adhesion isolation stent is provided, which is used to connect and expand the intrauterine anti-adhesion isolation stent described in the above aspect.
[0033] The expansion device comprises:
[0034] Spreaders; and
[0035] An outer sleeve sleeved outside the spreader;
[0036] The expander includes:
[0037] A spreading rod, one end of which is fixedly connected to the housing at the front end of the spreader, and the other end of which is connected to the uterine cavity anti-adhesion isolation bracket. The spreading rod is an opening and closing structure. When the spreading rod is closed, the uterine cavity anti-adhesion isolation bracket is folded; when the spreading rod is opened, the uterine cavity anti-adhesion isolation bracket is spread open;
[0038] A push screw is movably arranged in the housing of the spreader, and the spreader rod is opened by the push-out force of the top of the push screw;
[0039] A push rod, one end of which is movably disposed in the housing of the spreader and connected to the tail of the top screw, and the other end of which extends from the tail of the housing of the spreader to push the top screw to move axially in the spreader;
[0040] The housing of the spreader consists of:
[0041] A first sleeve is used to accommodate the top of the push rod and the tail of the top screw, and the push rod partially moves axially in the first sleeve and pushes the top screw;
[0042] A second sleeve, fixedly connected to the first sleeve;
[0043] A third sleeve, one end of which is sleeved inside the second sleeve, and the other end of which extends out from the second sleeve and is fixedly connected to the second sleeve; the third sleeve is used to accommodate a top screw, which moves axially inside the third sleeve, and the expansion rod is partially fixed inside an end of the third sleeve away from the second sleeve;
[0044] The outer sleeve is inserted from the front end of the expander and is used to accommodate the uterine cavity anti-adhesion isolation bracket and a part of the expander.
[0045] In some embodiments, the spreader rod comprises:
[0046] A first connecting rod, one end of which is fixed in the housing at the front end of the expander, and the other end of which extends out of the expander to connect to a support tube of the uterine cavity anti-adhesion isolation bracket;
[0047] A second connecting rod, one end of which is fixed in the housing at the front end of the expander, and the other end of which extends out of the expander to connect to another support tube of the uterine cavity anti-adhesion isolation bracket;
[0048] The pin passes through the first connecting rod and the second connecting rod inside the spreader to fix the spreader rod in the housing at the front end of the spreader.
[0049] In some embodiments, the outer sleeve is provided with scale markings; the outer sleeve also includes a positioning clamp, which is movably mounted on the outer sleeve; the expansion device also includes a measuring rod, which is provided with scale markings for measuring the uterine cavity depth value; the positioning clamp is slid according to the uterine cavity depth value so that the straight-line distance from the end face of the positioning clamp to the top of the uterine cavity anti-adhesion isolation bracket is equal to the uterine cavity depth value.
[0050] The embodiment of the present invention provides an anti-adhesion isolation stent for uterine cavity and a propping device thereof, which has at least one or part of the following advantages:
[0051] (1) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention prevents intrauterine adhesion through physical space isolation after being expanded in the uterine cavity, and is suitable for implantation after various intrauterine surgeries;
[0052] (2) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention can adjust its degradation speed in the uterine cavity through the structural dimensions of the support frame and the notch thereon, the thickness of the degradable diaphragm, etc., and can be adaptively designed according to the patient's physical condition to obtain a better postoperative recovery effect;
[0053] (3) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention has a high support strength and a large specific surface area through the cooperation of the diaphragm and the support frame, so that the pressure it receives can be evenly distributed;
[0054] (4) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention is made of degradable material and does not need to be removed again after implantation, thus preventing infection caused by the removal operation;
[0055] (5) The substances released by the intrauterine anti-adhesion isolation stent provided by the embodiment of the present invention during the degradation process also have good and long-term antibacterial effects;
[0056] (6) The expansion device provided in the embodiment of the present invention realizes the one-time expansion and release of the intrauterine anti-adhesion isolation stent in the uterine cavity through the expander. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] These and / or other aspects and advantages of the present invention will become apparent and readily understood from the following description of the preferred embodiments in conjunction with the accompanying drawings, in which:
[0058] Figure 1 It is an enlarged structural schematic diagram of an anti-uterine adhesion isolation stent according to an embodiment of the present invention;
[0059] Figure 2According to another embodiment of the present invention, Figure 1 The schematic diagram of the structure of the expansion device of the uterine cavity anti-adhesion isolation stent shown;
[0060] Figure 3 To cooperate Figure 2 A schematic diagram of the structure of the measuring rod when the expansion device is in use;
[0061] Figure 4 for Figure 2 A cross-sectional view of a spreader of the spreader device shown;
[0062] Figure 5 for Figure 4 A partially enlarged structural diagram of the front end of the spreader and its spreader rod is shown;
[0063] Figure 6 for Figure 5 An enlarged schematic structural diagram of the expansion rod is shown. DETAILED DESCRIPTION
[0064] The technical solution of the present invention is further specifically described below by examples and in conjunction with the accompanying drawings. In the specification, the same or similar reference numerals indicate the same or similar components. The following description of the embodiments of the present invention with reference to the accompanying drawings is intended to explain the overall inventive concept of the present invention and should not be construed as a limitation of the present invention.
[0065] The intrauterine anti-adhesion isolation stent can provide a support space inside the uterine cavity after the intrauterine surgery (such as artificial abortion, curettage, tumor resection, etc.) is completed, and prevent or reduce the intrauterine endometrial adhesion during the patient's postoperative recovery period through physical space isolation.
[0066] The uterine cavity anti-adhesion isolation bracket of the embodiment of the present invention is made of completely degradable materials, and the release process in the uterine cavity is a one-time operation. The uterine cavity anti-adhesion isolation bracket after release can conform to the internal space of the uterine cavity and can completely self-degrade after a controllable period. The uterine cavity anti-adhesion isolation bracket forms effective support and isolation for the uterine horns and the edge of the uterine cavity to avoid sliding. The overall force condition of the uterine cavity anti-adhesion isolation bracket is uniform, without local stress, high support strength, and a larger specific surface area can be obtained after being opened, so as to effectively prevent the uterine cavity and its uterine horns from re-adhesion. In addition, by the adaptive connection between the opening device and the uterine cavity anti-adhesion isolation bracket, it can be ensured that the uterine cavity anti-adhesion isolation bracket is smoothly detached from the opening device and fully opened in the uterine cavity.
[0067] refer to Figure 1, shows an intrauterine anti-adhesion isolation stent according to an embodiment of the present invention. The intrauterine anti-adhesion isolation stent (hereinafter referred to as the isolation stent) 100 includes a support frame 10 made of a degradable zinc alloy material and a degradable diaphragm 20, and the degradable diaphragm 20 is fixedly connected to the support frame 10; the degradable diaphragm 20 can be opened by pulling the support frame 10. When the isolation stent 100 is not in use, the degradable diaphragm 20 is in a folded state, and when the isolation stent 100 enters the uterine cavity, the degradable diaphragm 20 is in an open state.
[0068] In one example, the support frame 10 of this embodiment includes two support tubes 11, and at least one notch 12 is respectively arranged on the surface of the two support tubes 11. In the illustrated embodiment, three groups of notches are arranged on each support tube 11, and a certain distance is arranged between each group of notches, and each group of notches includes 6 to 10 notches 12; the degradable diaphragm 20 is fixed between the two support tubes 11 through all or part of the notches 12, for example, each notch 12 on a certain center line in the three groups is used to fix the degradable diaphragm 20, and the remaining other notches 12 are vacant (after the isolation bracket 100 is implanted, the body fluid in the uterine cavity enters the vacated notch 12 to promote degradation). The number of notches 12 set and whether they are evenly distributed on the same support tube 11 can be adapted and adjusted according to the actual use scenario. This example is only an illustrative example, and those skilled in the art should not be understood as a limitation of the present invention.
[0069] In one example, the shape of the notches 12 on the two support tubes 11 can be selected in a variety of ways, such as equilateral or unequal-sided squares, diamonds, ellipses, etc. Generally, the shape and length of each side of the notch 12 need to be customized according to the actual use scenario of the isolation stent 100, but its opening width is generally set in the range of 0.1 to 0.5 mm to fix the edge of the degradable diaphragm 20. Correspondingly, considering the time period of degradation after actual implantation in the uterine cavity, the thickness of the degradable diaphragm 20 is generally in the range of 0.2 to 0.4 mm. In order to facilitate the placement and fixation of the edge of the degradable membrane 20 in the notch 12, some protrusions may be reserved on the edge of the degradable membrane 20, and the protrusions are first embedded in the notch 12, and then the notch 12 is heated so that the notch 12 and the protrusions of the degradable membrane 20 are hot-pressed and bonded together, and the above hot-pressing and bonding process is repeated for each notch 12 and protrusion of the degradable membrane 20 used to fix the degradable membrane 20, so that the degradable membrane 20 is completely fixed on the two support tubes 11. Of course, those skilled in the art can understand that hot-pressing and bonding is only one of the technical means for fixing the degradable membrane 20, and should not be a limitation of the present invention.
[0070] In one example, the isolation stent 100 as a whole can be self-degraded in the uterine cavity, wherein the support frame 10 (two support tubes 11 in this embodiment) is made of a degradable zinc alloy material, and the degradable diaphragm 20 is made of a degradable polymer material. After the isolation stent 100 is implanted in the human uterine cavity, it does not need to be removed by surgery again, avoiding postoperative reinfection due to the presence of tail threads, etc., and it is also unnecessary to take hormone drugs, reducing the impact of drugs on the patient's body. The degradation speed of the isolation stent 100 can be adjusted by coupling the characteristic parameters of the support frame 10, the notch 12 or the degradable diaphragm 20.
[0071] In one example, the degradable zinc alloy material used to make the two support tubes 11 contains, in addition to zinc, at least one of Cu, Li, Mn, Mg, Ca, Sr, Fe, Ag, Co, Cr, Ti, Sn, Si, Se, and Ge, or any combination thereof.
[0072] Specifically, in the degradable zinc alloy material used in the present embodiment, the ratio of other alloy chemical elements can be: 0.01-5wt% Cu, 0.01-2wt% Li, 0.01-5wt% Mn, 0.01-5wt% Mg, 0.01-2wt% Ca, 0.01-5wt% Sr, 0.01-5wt% Fe, 0.01-5wt% Ag, 0.01-5wt% Co, 0.01-5wt% Cr, 0.01-5wt% Ti, 0.01-5wt% Sn, 0.01-5wt% Si, 0.01-5wt% Se, 0.01-5wt% Ge and some unavoidable impurity elements, and the sum of the weight percentages of the above alloy chemical elements and the zinc element is 100%. Of course, those skilled in the art can understand that in the actual production process of the isolation bracket 100, the composition and ratio of the above alloy chemical elements can be adjusted. This example is only an illustrative example, and those skilled in the art should not understand it as a limitation of the present invention.
[0073] Furthermore, zinc is an indispensable trace element in the human metabolic system. It is an essential element for more than 300 enzymes and 1,000 transcription factors to realize their functions. It is the second most abundant trace metal element in the human body after iron, and zinc is also the only metal element that appears in all enzymes. Zinc plays an important role in RNA and DNA metabolism, signal transduction and gene expression. About 10% of human proteins (about 3,000 kinds) need to be combined with zinc. When the zinc alloy material used in this embodiment is degraded in the human body, the Zn generated 2+It also has antibacterial and antimicrobial effects, and can maintain long-term antibacterial effects during the degradation process. This antibacterial effect is better than the effect of coating the antibacterial coating on the surface of the isolation stent used in the prior art, thereby further reducing the risk of infection and chronic inflammation in the human body.
[0074] In one example, the degradable polymer material used to make the degradable membrane 20 can be selected from the types commonly used in the medical field, including but not limited to, for example, polylactic acid-co-glycolic acid (PLGA), poly-L-lactide (PLLA), polydioxanone (PDO), polycaprolactone (PCL) or any combination thereof.
[0075] This embodiment uses polylactic acid-glycolic acid copolymer to make the degradable membrane 20, and the produced degradable membrane 20 needs to have a characteristic viscosity greater than or equal to 0.8dl / g. At the same time, the surface of the degradable membrane 20 should be free of defects, scratches, impurities, color differences, burrs, and other obvious defects. On the one hand, these defects will affect the fixation between the degradable membrane 20 and the support frame 10, and in severe cases, the degradable membrane 20 and the support frame 10 will fall off completely or partially when the isolation support 100 is not in use, or the degradable membrane 20 and the support frame 10 will be completely or partially separated after implantation in the uterine cavity, affecting the support effect of the isolation support 100; on the other hand, it will also affect the degradation speed and degradation effect of the isolation support 100 after entering the uterine cavity, thereby affecting the patient's postoperative recovery.
[0076] In one example, when designing and manufacturing the isolation stent 100 , the degradation rate thereof in the human uterine cavity can be adjusted by adjusting the characteristic parameters of the support frame 10 and the degradable diaphragm 20 .
[0077] Specifically, the degradation rate of the isolation bracket 100 is mainly related to the coupling of the structural dimensions of the support frame 10 (including the number and size of the notches 12 opened thereon) and the thickness of the degradable membrane 20. For example, the finer the structure of the support frame 20 (it can be that the cross section is reduced, the cross section is thinned, the cross section is hollow, etc., under the premise of ensuring the support strength), the faster the degradation rate of the isolation bracket 100; the smaller the thickness of the degradable membrane 20, the faster the degradation rate of the isolation bracket 100. In addition, in the human uterine cavity environment, the gap of the notch 12 can also accommodate and accumulate human body fluids. Therefore, the number of notches 12 is appropriately increased, on the one hand, the degradable membrane 20 can be tightened, and on the other hand, more human body fluids can be contacted, thereby promoting the isolation bracket 100 to further accelerate degradation. At the same time, the chemical substances (degradation products) released by the isolation bracket 100 during the degradation process help to reduce the pH value of human body fluids, and the reduction in pH value will promote the accelerated degradation of the support frame 10.
[0078] Specifically, characteristic parameters that can be used to adjust the degradation rate of the isolation stent 100 in the human uterine cavity include:
[0079] The length, outer diameter, wall thickness, cross-sectional area, cross-sectional diameter (generally inner diameter) or cross-sectional side length of the support frame 10 or any combination thereof;
[0080] The number, shape, area or side length of the slots 12 or any combination thereof;
[0081] The thickness of the separator 20 can be degraded.
[0082] In one example, the support frame 10 is generally a hollow structure with a length ranging from 33 to 42 mm, an outer diameter ranging from 1.3 to 2.3 mm, and a wall thickness less than or equal to 0.1 mm.
[0083] In one example, the number of the slots 12 is 20 to 30, and the slots 12 are generally in the shape of a long strip, with a long side ranging from 3 to 7 mm and a short side ranging from 0.3 to 0.5 mm.
[0084] In one example, the thickness of the degradable membrane 20 is in the range of 0.2 to 0.4 mm.
[0085] In one example, a group of specific characteristic parameters of the isolation bracket 100 of this embodiment are shown to further illustrate how to adjust the degradation rate of the isolation bracket 100 .
[0086] The support frame 10 is used as Figure 1 The two support tubes 11 shown are hollow straight tubes with circular cross-sections, and each support tube 11 is provided with three groups of notches 12 . The total number of notches 12 on each support tube 11 ranges from 20 to 30.
[0087] (1) When the outer diameter of the two support tubes 11 is 1.3-1.8 mm, the three groups of notches 12 on each support tube 11 are all long strip cross-sections and penetrate the support tube 11, and the cross-sectional area of each notch 12 is 0.9-2.2 mm 2 When the thickness of the degradable diaphragm 20 is 0.2 to 0.3 mm, the degradation time of the isolation stent 100 after implantation into the uterine cavity is 1 to 3 months.
[0088] (2) When the outer diameter of the two support tubes 11 is 1.3-2.3 mm, the three groups of notches 12 on each support tube 11 are all long strip cross-sections and penetrate the support tube 11, and the cross-sectional area of each notch 12 is 2.2-3.5 mm 2 When the thickness of the degradable diaphragm 20 is 5 to 10 μm, the degradation time of the isolation stent 100 after implantation into the uterine cavity is 3 to 6 months.
[0089] Therefore, by pre-designing and coupling the characteristic parameters of the isolation stent 100, the degradation rate of the isolation stent 100 in the human uterine cavity can be adjusted, and a more suitable isolation stent 100 with a controllable degradation rate can be designed and customized according to the actual patient's physical condition, illness or recovery situation.
[0090] Generally speaking, the isolation stent 100 of this embodiment can provide stable mechanical support for 15 to 30 days after being implanted in the uterine cavity, and can be completely degraded within 35 to 90 days. The degradation products are harmless to the human body, and the corrosion products and metal ions formed during this period can be excreted from the body through metabolism and menstruation.
[0091] In order to ensure the supporting strength of the support frame 20 of the isolation bracket 100 of this embodiment, this embodiment preferably uses a tube drawing process to manufacture the support frame 20.
[0092] In one example, taking the support tube 11 as an example, the specific process parameters in the process of forming the hollow tube by drawing process include:
[0093] When the pipe is drawn, the deformation range of a single pass is controlled within 5% to 25%, and the drawing rate is controlled within 0.15 to 5 mm / s;
[0094] After the pipe is continuously broken for a predetermined number of times (set to 3 times in this embodiment), an annealing treatment is performed, and the annealing temperature is controlled in the range of 125-325°C and the annealing time is 15-60 minutes;
[0095] Furthermore, taking a circular cross-section tube as an example, after the tube is drawn and formed, the outer diameter range of each support tube 11 is controlled to be 1.3-2.3 mm, the wall thickness is less than or equal to 0.1 mm, the length range is 33-42 mm, and the surface roughness should be less than or equal to 0.8 μm; at the same time, the room temperature yield strength of the support tube 11 should be greater than or equal to 150 MPa, the tensile strength should be greater than or equal to 200 MPa, and the elongation should be greater than or equal to 10%.
[0096] Of course, those skilled in the art will appreciate that the shape of the support tube 11 can be adjusted according to actual use, and its cross section can be circular, elliptical, square, unequal square or diamond cross section, etc. The above process, manufacturing and finished product structural parameters are only an illustrative example, and those skilled in the art should not be understood as a limitation of the present invention.
[0097] In one example, corresponding to the structure of the support tube 11, and facilitating the subsequent implantation and opening of the isolation stent 100 by the expansion device, the shape of the degradable membrane 20 can be fan-shaped or trapezoidal, such as Figure 1In the embodiment shown, the shape of the degradable membrane 20 is approximately a trapezoidal surface, and the degradable membrane 20 forms a long side and a short side respectively above and below the figure, the length range of the long side is controlled to be 26 to 35 mm, the length range of the short side is controlled to be 10 to 12 mm, and the vertical distance between the long side and the short side, that is, the height range of the degradable membrane 20 is controlled to be 27 to 40 mm, and the thickness range is controlled to be 0.2 to 0.4 mm; the other two oblique sides of the degradable membrane 20 are respectively fixed by hot pressing and bonding through the corresponding notches 12 on the two support tubes 11.
[0098] refer to Figure 2 , shows a spreading device 200 of an intrauterine anti-adhesion isolation stent according to another embodiment of the present invention, which is used to connect and spread the intrauterine anti-adhesion isolation stent 100 of the above-mentioned embodiment.
[0099] The spreading device 200 comprises a spreader 210 and an outer sleeve 220 sleeved outside the spreader 210. Figure 2 ) includes a spreading rod 211 for connecting two support tubes 11 of the intrauterine anti-adhesion isolation stent (hereinafter referred to as the isolation stent) 100 of this embodiment (correspondingly, one end of the two support tubes 11 is respectively provided with an interface or a positioning groove that can be connected to the spreading rod 211, which is not shown in the figure); after the isolation stent 100 is connected to the spreader 210, the outer sleeve 220 is inserted from the front end of the spreader 210, so as to fix and protect the unused isolation stent 100, and at the same time, it also plays a role in guiding, positioning and conveying when the isolation stent 100 is implanted later.
[0100] Specifically, the expander 210 includes an outer shell, one end of the expander rod 211 is fixedly connected to the inner shell of the front end of the expander 210, and the other end is connected to the isolation bracket 100 through the interface or positioning groove (not shown) of the two support tubes 11; the expander rod 211 is an opening and closing structure, when the expander rod 211 is closed, the isolation bracket 100 is folded; when the expander rod 211 is opened, the isolation bracket 100 is expanded.
[0101] Furthermore, in the housing of the spreader 210, a top screw 212 and a push rod 213 are sequentially connected behind the spreader rod 211. When the push rod 213 is pushed to move toward the front end of the spreader 210, the push rod 213 pushes the top screw 212, and the top screw 212 pushes the spreader rod 211, and the spreader rod 211 is opened under the push force of the top screw 212, thereby spreading the isolation bracket 100.
[0102] In one example, the outer sleeve 220 further includes a positioning clamp 221, which is movably mounted on the outer sleeve 220. At the same time, a scale mark (not shown) is also provided on the outer sleeve 220. When the isolation stent 100 is actually used, the expansion device 200 needs to be inserted into the human uterine cavity to a predetermined depth, and then expanded by the expander 210. Therefore, the predetermined insertion depth needs to be clearly determined each time the operation is performed. At this time, a measuring rod 300 (see Figure 3 ), the measuring rod 300 is provided with a scale mark (not shown), which is used to be inserted into the uterine cavity to measure the uterine cavity depth value in advance. After obtaining the actual uterine cavity depth value, by sliding the positioning clamp 221 to the corresponding scale position of the scale mark of the outer sleeve 220, that is, the linear distance from the end face of the positioning clamp 221 (which can be any one of the front and rear end faces) to the isolation bracket 100 (the isolation bracket 100 is folded and stored in the outer sleeve 220 at this time) away from one end of the spreader 210 is equal to the actual uterine cavity depth value measured by the measuring rod 300. When the isolation bracket 100 is implanted later, the spreader 210 with the outer sleeve 220 is inserted into the positioning clamp 221 to complete the insertion process and then enter the release process of the isolation bracket 100.
[0103] In one example, the outer sleeve 220 is further provided with a protective cap 222 at its front end (the front end of the stretcher 210). When the isolation bracket 100 is not in use, it is sleeved on the front end of the stretching device 200 (the front end of the stretcher 210). The isolation bracket 100 connected to the front end of the stretcher 210 is protected by the protective cap 222. When in use, the protective cap 222 needs to be removed first.
[0104] In one example, the outer sleeve 220 is also equipped with a fixing clip 223. Since the outer sleeve 220 can slide outside the spreader 210, when the outer sleeve 220 needs to be fixed at a certain position of the spreader 210, the fixing clip 223 can be used to clamp and fix it.
[0105] In one example, reference Figure 4 , showing the internal components and connection structure of the spreader 210. First, the outer shell of the spreader 210 is divided into three parts. Figure 4 From left to right, the first sleeve 214, the second sleeve 215 and the third sleeve 216 are included in sequence.
[0106] The first sleeve 214 is used to accommodate the top of the push rod 213 and the tail of the push screw 212 . The push rod 213 can partially move axially in the first sleeve 214 and push the push screw 212 .
[0107] The second sleeve 215 is fixedly connected to the first sleeve 214. Since the expander 210 is a thin rod structure as a whole (the outer diameter of the expander 210 in this embodiment is about 5 mm), the second sleeve 215 is sleeved at the connection between the push rod 213 and the top screw 212 to strengthen the support.
[0108] One end of the third sleeve 216 is sleeved inside the second sleeve 215, and the other end extends out from the second sleeve 215. The third sleeve 216 is fixedly connected to the second sleeve 215 and cannot slide. The third sleeve 216 is used to accommodate the top screw 212, and the top screw 212 can move axially inside the third sleeve 216. At the same time, the front end of the third sleeve 216 is also used to fix the support rod 211.
[0109] In one example, a spring member (not shown) is sleeved on the tail end of the top screw 212 , and the push rod 213 is ensured to push the top screw 212 slowly and stably through the friction with the inner wall of the third sleeve 216 .
[0110] In one example, one end of the push rod 213 is movably disposed in the outer shell of the spreader 210 (i.e., the first sleeve 214) for connecting the top screw 212, and the other end extends from the rear end of the outer shell of the spreader 210; in order to facilitate manual pushing of the push rod 213 during actual operation so that it can move smoothly and slowly along the axial direction within the spreader 210, a push handle 217 is provided at the rear end of the push rod 213, which is fixedly connected to the rear end of the push rod 213 and acts as a handle. The push handle 217 is held to push the push rod 213.
[0111] In one example, combining Figure 5 and Figure 6 , showing the position of the spreading rod 211 in the spreader 210 and the specific structure of the spreading rod 211. The spreading rod 211 includes the following three parts: a first connecting rod 211a, a second connecting rod 211b and a pin 211c.
[0112] One end of the first connecting rod 211 a is fixed in the housing (ie, the third sleeve 216 ) at the front end of the spreader 210 , and the other end extends out of the spreader 210 to connect to a supporting tube 11 of the isolation bracket 100 .
[0113] One end of the second connecting rod 211 b is fixed in the housing (ie, the third sleeve 216 ) at the front end of the spreader 210 , and the other end extends out of the spreader 210 to connect to another supporting tube 11 of the isolation bracket 100 .
[0114] The pin 211c passes through the first connecting rod 211a and the second connecting rod 211b inside the spreader 210, and fixes the spreader rod 211 inside the housing (ie, the third sleeve 216) at the front end of the spreader 210.
[0115] In one example, the front end of the top screw 212 has a conical head. When the top screw 212 moves toward the spreading rod 211 and pushes against one end of the first connecting rod 211a and the second connecting rod 211b in the spreader 210, the top screw 212 is continuously pushed by the push rod 213, and the conical head of the top screw 212 can ensure that the first connecting rod 211a and the second connecting rod 211b are fully opened to Figure 6 In the enlarged view of the expansion rod 211 shown, when the first connecting rod 211a and the second connecting rod 211b are fully opened, the two supporting tubes 11 of the isolation bracket 100 connected thereto are also fully opened, thereby fully expanding the isolation bracket 100.
[0116] In one example, the manufacturing materials of the spreader 210 include stainless steel and polytetrafluoroethylene. For example, the spreader rod 211 is generally made of stainless steel metal material because it needs to be connected to the support tube 11 of the isolation bracket 100. In order to make the two connect well and ensure that the isolation bracket 100 is smoothly spread and detached from the spreader rod 211; while other parts, such as the outer sleeve 220, mainly play the role of protecting the spreader 210 and conveying and positioning. In order to save material costs, polytetrafluoroethylene can be used. The outer shell of the spreader 210 is generally made of polycarbonate (PC) material, which can save material costs and provide sufficient support strength.
[0117] In one example, in combination with the isolation bracket 100 and the expansion device 200 of this embodiment, the method and process of using the expansion device 200 are specifically described.
[0118] (1) Use the measuring rod 300 to determine the position and depth of the uterine cavity and obtain the uterine cavity depth value (the outer diameter of the dilator 210 is generally 5 mm, and the cervical opening can be pre-dilated according to actual operation needs);
[0119] (2) Remove the protective cap 222. At this time, the fixing clip 223 is clamped on the outer sleeve 220. The positioning clamp 221 is adjusted according to the uterine cavity depth value so that the straight-line distance from the front end of the outer sleeve 220 (the front end of the expander 210) to one end face of the adjusted positioning clamp 221 is equal to the uterine cavity depth;
[0120] (3) According to the position of the positioning clamp 221, the expander 210 with the outer sleeve 220 is inserted into the uterine cavity until the bottom of the uterine cavity, the expander 210 is supported by hand and the fixing clip 223 on the outer sleeve 220 is opened, the outer sleeve 220 is withdrawn to the cervical os, and the outer sleeve 220 is clamped and fixed with the fixing clip 223;
[0121] (4) Slowly push the push handle 217 to the maximum distance it can travel until the push handle 217 can no longer move forward, indicating that the front end conical head of the push screw 212 has pushed open the expansion rod 211, that is, the isolation stent 100 has been fully expanded in the uterine cavity;
[0122] (5) Completely withdraw the distraction device 200 from the uterine cavity to complete the implantation of the isolation stent 100.
[0123] The embodiment of the present invention provides an anti-adhesion isolation stent for uterine cavity and a propping device thereof, which has at least one or part of the following advantages:
[0124] (1) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention prevents intrauterine adhesion through physical space isolation after being expanded in the uterine cavity, and is suitable for implantation after various intrauterine surgeries;
[0125] (2) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention can adjust its degradation speed in the uterine cavity through the structural dimensions of the support frame and the notch thereon, the thickness of the degradable diaphragm, etc., and can be adaptively designed according to the patient's physical condition to obtain a better postoperative recovery effect;
[0126] (3) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention has a high support strength and a large specific surface area through the cooperation of the diaphragm and the support frame, so that the pressure it receives can be evenly distributed;
[0127] (4) The intrauterine anti-adhesion isolation stent provided in the embodiment of the present invention is made of degradable material and does not need to be removed again after implantation, thus preventing infection caused by the removal operation;
[0128] (5) The substances released by the intrauterine anti-adhesion isolation stent provided by the embodiment of the present invention during the degradation process also have good and long-term antibacterial effects;
[0129] (6) The expansion device provided in the embodiment of the present invention realizes the one-time expansion and release of the intrauterine anti-adhesion isolation stent in the uterine cavity through the expander.
[0130] Although some embodiments of the present general inventive concept have been shown and described, it will be appreciated by those skilled in the art that changes may be made to these embodiments without departing from the principles and spirit of the present general inventive concept, the scope of which is defined by the claims and their equivalents.
Claims
1. A uterine cavity anti-adhesion isolation stent, comprising: The support frame comprises at least two support tubes, wherein the at least two support tubes are made of a degradable zinc alloy material; A notch is provided on the surface of each of the at least two support tubes, and at least one notch is provided on the surface of each support tube; A degradable membrane, disposed between the at least two support tubes, and fixedly connected to the at least two support tubes through the notch, wherein the degradable membrane is configured to be foldable or unfoldable; The degradation rate of the intrauterine anti-adhesion isolation stent is adjusted by coupling the characteristic parameters of the support frame, the notch or the degradable diaphragm.
2. The intrauterine anti-adhesion isolation stent according to claim 1, characterized in that: The degradable zinc alloy material contains other alloy chemical elements besides zinc, including at least one of Cu, Li, Mn, Mg, Ca, Sr, Fe, Ag, Co, Cr, Ti, Sn, Si, Se, Ge, or any combination thereof.
3. The intrauterine anti-adhesion isolation stent according to claim 2, characterized in that: The number of the at least two support tubes is two, each support tube is a hollow tube section, each support tube has an outer diameter ranging from 1.3 to 2.3 mm, a wall thickness less than or equal to 0.1 mm, a length ranging from 33 to 42 mm, and a surface roughness less than or equal to 0.8 μm; The at least two support tubes are formed by using a tube through a drawing process; When the tube is drawn, the deformation range of a single pass is 5% to 25%, and the drawing rate range is 0.15 to 5 mm / s; The pipe is subjected to annealing treatment each time it is continuously broken to a predetermined number of times, the annealing temperature is 125-325°C, and the annealing time is 15-60 minutes; The room temperature yield strength of the degradable zinc alloy material is greater than or equal to 150 MPa, the tensile strength is greater than or equal to 200 MPa, and the elongation is greater than or equal to 10%.
4. The uterine cavity anti-adhesion isolation stent according to claim 3, characterized in that: The degradable diaphragm is made of a degradable polymer material, and the intrinsic viscosity is greater than or equal to 0.8 dl / g. The degradable polymer material is one of polylactic acid-co-glycolic acid, poly-L-lactide, polydioxanone, polycaprolactone, or any combination thereof; The degradable membrane is in the shape of a sector or a trapezoid, the length of the long side of the sector or trapezoid is in the range of 26 to 35 mm, the length of the short side is in the range of 10 to 12 mm, the height is in the range of 27 to 40 mm, and the thickness of the degradable membrane is in the range of 0.2 to 0.4 mm.
5. The intrauterine anti-adhesion isolation stent according to claim 1, characterized in that: The characteristic parameters include: one of the length, outer diameter, wall thickness, cross-sectional area, cross-sectional diameter, and cross-sectional side length of the support frame, or any combination thereof; in, The length of the support frame ranges from 33 to 42 mm; The outer diameter of the support frame ranges from 1.3 to 2.3 mm; The wall thickness of the support frame is less than or equal to 0.1 mm; The characteristic parameters also include: one of the number of the slots, the shape of the slots, the area of the slots, the side length of the slots, or any combination thereof.
6. The intrauterine anti-adhesion isolation stent according to claim 5, characterized in that: The notch passes through the support tube or passes through the wall surface of the support tube; The number of the notches formed on each support tube is 20 to 30; The notch area ranges from 0.9 to 3.5 mm 2 ; The length of the notch side includes a long side and a short side, the long side ranges from 3 to 7 mm, and the short side ranges from 0.3 to 0.5 mm.
7. The uterine cavity anti-adhesion isolation stent according to claim 5, characterized in that: The characteristic parameters also include: the thickness of the degradable membrane, and the thickness ranges from 0.2 to 0.4 mm.
8. The intrauterine anti-adhesion isolation stent according to any one of claims 1 to 7, characterized in that: After the intrauterine anti-adhesion isolation stent is implanted into the uterine cavity, the degradation rate of the intrauterine anti-adhesion isolation stent varies as follows: Increases as the length and / or cross-section of the support decreases; As the number of the notches increases; It increases as the thickness of the degradable membrane decreases.
9. The intrauterine anti-adhesion isolation stent according to claim 8, characterized in that: When the outer diameters of the two support tubes are 1.3-1.8 mm, the area of the notches is 0.9-3.5 mm 2 When the thickness of the degradable membrane is 0.2 to 0.3 mm, the degradation time of the intrauterine anti-adhesion isolation stent after implantation into the uterine cavity is 1 to 3 months.
10. The intrauterine anti-adhesion isolation stent according to claim 8, characterized in that: When the outer diameters of the two support tubes are 1.3-2.3 mm, the area of the notch is 2.2-3.5 mm 2 When the thickness of the degradable membrane is 5 to 10 μm, the degradation time of the intrauterine anti-adhesion isolation stent after implantation into the uterine cavity is 3 to 6 months.
11. A spreading device for an intrauterine anti-adhesion isolation stent, used for connecting and spreading the intrauterine anti-adhesion isolation stent according to any one of claims 1 to 10, the spreading device comprising: Spreader; and An outer sleeve sleeved outside the spreader; Wherein, the expander comprises: A spreading rod, one end of which is fixedly connected to the housing at the front end of the spreader, and the other end of which is cooperatively connected to the uterine cavity anti-adhesion isolation bracket. The spreading rod is an opening and closing structure. When the spreading rod is closed, the uterine cavity anti-adhesion isolation bracket is folded; when the spreading rod is opened, the uterine cavity anti-adhesion isolation bracket is spread open; A push screw is movably arranged in the housing of the spreader, and the spreader rod is opened by the push-out force of the top of the push screw; A push rod, one end of which is movably disposed in the housing of the spreader and connected to the tail of the top screw, and the other end of which extends from the tail of the housing of the spreader, and the push rod is used to push the top screw to move axially in the spreader; The housing of the expander comprises: A first sleeve, used to accommodate the top of the push rod and the tail of the top screw, wherein the push rod partially moves axially in the first sleeve and pushes the top screw; A second sleeve, fixedly connected to the first sleeve; a third sleeve, one end of the third sleeve is sleeved inside the second sleeve, the other end of the third sleeve extends out from the second sleeve, the third sleeve is fixedly connected to the second sleeve, the third sleeve is used to accommodate the top screw, the top screw moves axially inside the third sleeve, and the expansion rod is partially fixed inside the end of the third sleeve away from the second sleeve; The outer sleeve is inserted from the front end of the expander and is used to accommodate the uterine cavity anti-adhesion isolation bracket and a part of the expander.
12. The expansion device according to claim 11, characterized in that: The expansion rod comprises: A first connecting rod, one end of which is fixed in a housing at the front end of the spreader, and the other end of which extends out of the spreader to connect to a support tube of the uterine cavity anti-adhesion isolation bracket; A second connecting rod, one end of which is fixed in the housing at the front end of the spreader, and the other end of which extends out of the spreader to connect to another support tube of the uterine cavity anti-adhesion isolation stent; A pin passes through the first connecting rod and the second connecting rod inside the spreader to fix the spreader rod in the housing at the front end of the spreader.
13. The expansion device according to claim 12, characterized in that: The outer sleeve is provided with a scale mark; The outer sleeve further comprises a positioning clamp, which is movably sleeved on the outer sleeve; The expansion device further comprises a measuring rod, on which a scale mark is arranged for measuring the depth value of the uterine cavity; The positioning clamp is slid according to the uterine cavity depth value so that the straight-line distance from the end surface of the positioning clamp to the top end of the uterine cavity anti-adhesion isolation bracket is equal to the uterine cavity depth value.
Citation Information
Patent Citations
Anti-intrauterine adhesion device
CN106344230A
Degradable metal material uterine cavity support releasing system
CN117084836A
Intrauterine adhesion prevention device used after uterine cavity operation of obstetrics and gynecology department
CN216439289U
Intrauterine device for controlled drug release
WO2022029780A1
